Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental dual-targeted cell therapy for hard-to-treat lymphoma tested in early trial

NCT ID NCT06295549

First seen Jan 04, 2026 · Last updated May 24, 2026 · Updated 19 times

Summary

This early-phase trial tested a new cell therapy called LUCAR-G39P in 11 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy uses a patient's own immune cells that are modified to target two markers (CD19 and CD20) on cancer cells. The main goals were to check safety, find the right dose, and measure how long the modified cells last in the body. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, 226001, China

  • Beijing Gobroad Hosptial

    Beijing, 102206, China

  • Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital

    Nanjin, Jiangsu, 210029, China

Conditions

Explore the condition pages connected to this study.